ecrin-mdr-crcClinical2017MSIChemotherapyActivated Protein C ResistanceResistance, APCColorectal carcinomaColorectal NeoplasmsColoRectal CancerColorectal CarcinomaMsiChemotherapyActivated Protein C ResistanceResistance, ApcColorectal CancerColorectal NeoplasmsInterventionalhttps://newmdr.ecrin.org/Study/2231288NetherlandsBelgiumItalySpain11ColorectalAtezolizumabBevacizumabECRIN MDRTerminatedfalseStudy With Atezolizumab Plus Bevacizumab in Patients With Chemotherapy Resistant, MSI-like, Colorectal CancerThe primary objective of this study is to determine the anti-tumor activity, as measured by overall response rate (ORR) of atezolizumab in combination with bevacizumab in patients with chemotherapy resistant CRC and positivity for MSI-like molecular signature. This is an international, open-label single arm (non-randomized), one-stage phase II trial.2017-11-152231288NCT029826942016-002001-19